Convenient Location

8054 Yonge St. Thornhill. Just south of the intersection of Yonge and HWY 7/407

About Referrals

You need to be referred by your physician. Click here for information.

Covered by OHIP?

Most services are covered by the Ontario Health Insurance Plan (OHIP)

Convenient Location

8054 Yonge St. Thornhill. Just south of the intersection of Yonge and HWY 7/407

Patient Referral Form

You need to be referred by your physician. Click to download your form here.

Waiting Time

Your timeframe depends on the type of procedure.

OHIP Covered Services

Most services are covered by the Ontario Health Insurance Plan (OHIP)

WILDERMAN MEDICAL CLINIC

Investigator Initiated Trials

Wilderman Medical Clinic strives to be at the forefront of research and innovation. Our investigator-initiated trials are led by qualified staff and by physician researchers with over 10 years of clinical research experience.

Similarly to industry-initiated trials, physician-initiated trials have to go through the approval process, data collection, and analysis which can take up to several years.

The goal of our trials is to analyze data collected over many years, as well as prospectively, and establish patterns that can potentially be used to establish more efficient methods, treatment approaches, and measuring tools for delivering care to patients with chronic pain.

Wilderman Medical Clinic is currently looking to recruit volunteers with chronic pain conditions for the following studies:

Wilderman Medical Clinic is conducting a study to provide evidence of the validity of a new pain measurement tool. This tool will be used for the evaluation of the treatment effectiveness of corticosteroid injections for pain relief in patients with osteoarthritis of the knee. Osteoarthritis produces pain in the knee that is typically worsened by activities such as long distance walking. Corticosteroid injections into the knee joint are usually prescribed to treat the pain associated with osteoarthritis.

There are currently no well-established tools that can accurately measure the percentage and duration of pain relief. The new, developed within Wilderman Medical Clinic, Integral of Pain Relief (IPR) is a pain measurement tool that assesses two significant pain relief dimensions: (1) the percentage of pain relief, and (2) the duration of pain relief. Both factors are reported by the patient and provide important information about whether and to what extent a treatment provides relief for patients.

Benefits to participate in the study:

  • Your medical condition will be closely monitored during study period.
  • You will receive an individual pain diary. Keeping this pain diary helps to improve overall pain management, allows the assessment of pain dynamics, and gives a better understanding of what works best to alleviate your pain.
  • Your family doctor will be updated in case of a change in your health condition.
  • Your participation with us will help to improve pain relief interventions and treatment plans for other patients with chronic pain conditions like osteoarthritis of the knee.

Preliminary eligibility criteria

  • You must be available to participate in this trial for up to 13 weeks.
  • You must be over the age of 40.
  • You must have a confirmed diagnosis of knee osteoarthritis and have knee pain  more than 15 days in a month.
  • You must regularly receive corticosteroid injections or have considered receiving corticosteroid injections into the knee joint.

Further requirements will be reviewed with the doctor and trial personnel at the next stage and the evaluation.

To find out if you are eligible to participate in this study, please call (905) 886-1212 ext: 204 or e-mail: [email protected]

Our Completed Studies and Publications

Repeated Intravenous Lidocaine Infusions for Patients with Fibromyalgia: Higher Doses of Lidocaine Have a Stronger and Longer-Lasting Effect on Pain Reduction

Wilderman Medical Clinic reviewed and analyzed the clinical database of 74 patients with fibromyalgia whose pain was treated with lidocaine infusions. Study participants reported an average reduction of their pain intensity scores by 2.41–3.62 points immediately after the lidocaine infusion which corresponded to 30.51–46.71% of short-term pain relief.

This trend of pain relief was closely maintained at follow-up, with patients reporting average pain relief from 30.23% to 40.68% that lasted for 8.68 -17.54 days on average depending on the dose of lidocaine and the addition of magnesium. Our study results demonstrated that increased doses of intravenous lidocaine (up to 7.5mg/kg of adjusted body weight) are effective and safe in a significant number of patients with fibromyalgia. With higher doses of lidocaine pain relief was sustained in duration and lasted longer after the treatment.

The results of this study were published in the Journal of Pain Medicine in 20202. The full text of the article is available here.

Igor Wilderman, MD, CCFP, FCFP, DAAPM, Olga Pugacheva, PhD, Vsevolod (Sev) Perelman, MD, MSc, CCFP(EM), FCFP, CEUS, CHSE-A, Michael C T Wansbrough, MD, MSc, CCFP(EM), CEUS, DTM&H, DLSTMH CHSE, Yuri Voznyak, HBSc, Lukasz Zolnierczyk, HBSc, Repeated Intravenous Lidocaine Infusions for Patients with Fibromyalgia: Higher Doses of Lidocaine Have a Stronger and Longer-Lasting Effect on Pain Reduction,Pain Med. 2020;21(6):1230-1239., https://doi.org/10.1093/pm/pnz251

Meniscus-Targeted Injections for Chronic Knee Pain Due to Meniscal Tears or Degenerative Fraying: A Retrospective Study

Wilderman Medical Clinic demonstrated a substantial benefit from meniscus-targeted corticosteroid injections (20 and 40 mg triamcinolone) into the painful knee.

We analyzed the electronic medical records of 175 patients who had meniscal tears or degenerative fraying and were treated with meniscal-targeted injections. Ultrasound-guided meniscus-targeted corticosteroid injections produced 5.68 weeks of pain relief on average with a decrease in pain intensity score of 2.14 points at follow-up visits. The results of this study were published in the Journal of Ultrasound Medicine in 20191.

You can read here the full text of the article.

Wilderman I, Berkovich R, Meaney C, Kleiner O, Perelman V. Meniscus-Targeted Injections for Chronic Knee Pain Due to Meniscal Tears or Degenerative Fraying: A Retrospective Study. J Ultrasound Med. 2019;38(11):2853-2859. doi:10.1002/jum.14987

A Qualitative Study to Explore Patient Perspectives of Prophylactic Treatment with OnabotulinumtoxinA for Chronic Migraine

Introduction: OnabotulinumtoxinA (OBT-A) is one of the most studied prophylactic treatments for chronic migraine. Large clinical trials, and now real-world studies, continue to provide evidence to support the use of OBT-A as an effective treatment to manage chronic migraines. The objective of this study was to explore patient experience and perception of prophylactic treatment with OBT-A for chronic migraine.

Click here to read the full article.

Canadian Centre for Clinical Trials

If you are interested in learning about our current trials please visit our website at: www.clinicaltrialscanada.com